Immune marker playbooks support vaccine development
CEPI and PATH are joining forces to create playbooks that map all available research into specific immune markers that indicate protection against target viruses with epidemic or pandemic potential.
Supported by $8 million in funding from CEPI, these research and development (R&D) manuals could hold important insights for scientists, vaccine developers and regulators to more quickly and easily determine whether a vaccine candidate will generate protective immunity against certain deadly pathogens.
This includes viruses like monkeypox, Lassa, Zaire ebolavirus, Sudan ebolavirus, and Marburg.
Specific immune markers that signal protection against infection or disease and may reliably predict the level of a vaccine’s effectiveness are known as correlates of protection (CoP). CoPs have been used to advance the approval of vaccine candidates when large-scale efficacy trials are not possible because there are too few cases of a disease or because outbreaks are too explosive or sporadic.
While there is a growing body of research identifying potential immune markers for different epidemic diseases, scientists lack alignment when it comes to the tools and approaches used to measure these markers, making it difficult to compare findings and define or discover a CoP.
“Immune markers are one of the holy grails in the vaccine field, acting as a biological gauge to infer whether a vaccine candidate provides sufficient immunity and can advance to later testing or regulatory approvals,” explained Dr Kent Kester, Executive Director Vaccine R&D, CEPI. “However, little is known about what biomarker equates to protection for some CEPI priority pathogens leaving developers somewhat in the dark.
“These playbooks could help us to more rapidly prepare and prioritise vaccines with promising immune profiles even before a virus hits, supporting CEPI’s goal to develop vaccines against outbreaks in as little as 100 days.”
Diana Turner, Senior Digital Content Editor, DDW
